Latest Revenue Guidance News

Aroa Biosurgery’s latest business update reveals promising clinical outcomes from its Myriad trauma study and evolving reimbursement policies that could reshape its market position. The company also projects solid revenue growth for FY26, supported by strategic commercial initiatives.

Aroa Biosurgery reaffirms strong FY26 guidance, buoyed by favourable US Medicare reimbursement for Symphony and promising trauma study results for Myriad.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

A handful of small caps ripped higher, but plenty still slipped even after good news. This week’s biggest moves came from a platform partnership win, a reinstated stock, and a cash settlement that removed a long-running dispute.

Weebit Nano has landed its largest customer yet with Texas Instruments licensing its ReRAM technology, while achieving key technical milestones and doubling its revenue guidance for FY26.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

TradeWindow reports solid growth in recurring revenue and average revenue per customer but lowers its FY26 trading revenue guidance due to softer transactional volumes in Q3.

Ava Risk Group reports a softer first half with delayed orders impacting revenue, but anticipates a robust recovery in the second half backed by new contracts and a strategic investment.

Janus Electric reports operational progress with validated technology and increased revenue, while focusing on commercial execution and cost discipline under new CEO Ben Hutt. Funding remains a critical factor for sustaining growth.

Etherstack has reported a record-breaking 70% revenue increase in FY25, driven by major contracts and strong cashflow, and is poised for further robust growth in FY26.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Change Financial Limited has reported a record revenue quarter driven by its Vertexon platform growth and new client wins, prompting an upgrade to its FY26 financial guidance.